Abstract Objective: The outcomes for patients after endovascular treatment of abdominal aortic aneurysm (AAA) are determined primarily by the endpoints of death and endoleaks, the latter representing continued risk of rupture. The data of a multicentre registry were analysed with regard to the early outcome of stent-graft procedures for AAA and the complications associated with this treatment. In addition, the results during follow-up were analysed by determining mortality and endoleak development as separate endpoints and as a combined endpoint defined as endoleak-free survival. Setting: 38 European institutions of Vascular Surgery collaborating in a multicentre registry project. Patients and methods: 899 patients with AAA underwent between May 1994 and March 1998 elective endovascular repair (818 men and 81 women; mean age 69 years). 80 (8.9%) of the patients had medical conditions that excluded them from open repair. 818 (91%) of patients had a bifurcated device, 63 (7%) had a straight tube graft, and only 18 (2%) had an aorto-uniiliac device. Clinical examination and contrast-enhanced computed tomography was performed at fixed follow-up intervals to assess increase or decrease of the maximum transverse diameter (MTD). Endoleaks observed at follow-up were discriminated into persistent endoleak and temporary endoleak. The latter is defined as single time observed endoleaks or with two or more negative imaging studies between observed endoleaks. Life-table analyses were used to calculate the rates of freedom-from-endoleak (no endoleak at any time), freedom-from-persistent endoleak (no persistent endoleak), patient survival, and persistent-endoleak-free-survival. Results: The median follow-up of this patient series was 6.2 months. The ratio between observed and expected follow-up data was 82% for the overall follow-up period. However, at 18 months of follow-up this rate was only 45%. The number of patients followed during this period was sufficient to allow statistically meaningful assessment. The MTD in patients with temporary endoleaks demonstrated a significant decrease at 6 to 12 months compared to preoperative values (mean 57 and 53 respectively, p Z 0.004). In patients with persistent endoleaks there was no change between the preoperative and 6-month MTD (mean 57 and 60 mm respectively). At 6 and 18 months freedom-from-endoleak was 83% and 74% and freedom-frompersistent endoleak was 93% and 90%, respectively. The 18-month cumulative patient survival was 88% and the main outcome measure, the persistent endoleak-free-survival was 79%. Conclusions: The MTD decreases in patients with temporary endoleak, but not in patients with persistent endoleak. Therefore, the use of the rate of freedom-from-persistent endoleak, reflecting absence of persisting endoleaks to estimate the prognosis with regard to the AAA, is justified. Determining persistent endoleak-free survival appears a rational approach to provide a realistic outlook for patients with stent-grafted AAA. The observed 18-month endoleak-free survival reflects a satisfactory mid-term result. ª
Introduction
Following the initial successful application of stent-graft treatment by Parodi et al. in 1991 the short-term efficacy of endovascular abdominal aortic aneurysm (AAA) repair has been documented in a number of publications. [1] [2] [3] [4] [5] [6] However, with regard to mid-and long-term success much uncertainty remains. Most studies dealing with the outcome of endovascular treatment of AAA have reported on small numbers of patients. Usually follow-up results were not presented in lifetable or Kaplan-Meier format, and the outcomes have not been assessed from the patient's perspective. Rather, the physician's view has been considered, taking into account primarily procedural aspects such as access, graft deployment and function. The investigation of device failure and the reporting of these events is essential to further appreciate the advantages and disadvantages of endovascular AAA treatment. Technical failures can perhaps be accepted if the problem is resolved by a secondary endovascular intervention or even by a surgical procedure.
From the patient's perspective the possibility of dying, either from a related or unrelated cause, is of greatest relevance. Therefore, survival rate over time is the principal risk to be assessed for the patient. But endoleaks are also important. If an endoleak persists, the aneurysm remains at risk of rupture. Like survival, the absence of endoleak is a timedependent outcome that may best be represented in a lifetable format as rate of freedom-from-endoleak. Moreover, one may distinguish between freedom-from-endoleak for absence of any endoleak, and freedom-from-persistent endoleak if only a persistent endoleak is the event of interest. Considering mortality and persistent endoleak as a combined endpoint, defined as "persistent-endoleak-free survival" appears a simple and practical approach to provide a realistic prognosis to a patient of what can be expected if he or she chooses to undergo this form of treatment.
This report documents the results of a multicentre registry, organised by the "EUROSTAR" collaborators' group, with regard to the procedural and follow-up data of patients treated by stent-graft techniques in a large number of European vascular institutions. 7 The early outcome and perioperative complications are outlined. In addition, with regard to the follow-up period, freedom-from-endoleak, freedom-from-persistent endoleak, patient survival and persistent endoleak-free survival rates are assessed.
Because there is considerable variation with regard to the estimated rates of complications and endoleaks between different institutions, this large-scale study was performed to provide a realistic appraisal of the outcome of endovascular AAA repair in Europe.
Methods
The study period extended from April 1994 to April 1998. Two periods of patient enrolment could be distinguished.
1
Five hundred and thirty-five patients operated upon after 1st July 1996 had their procedures notified to the EURO-STAR Data Registry Center prior to operation. Data on patients operated upon before the 1st July 1996 were retrieved from hospital notes and other records retrospectively. This cohort, which consisted of 364 patients, was treated in 19 centres. Therefore, this study involved the data on a total of 899 patients. They were provided from 38 centres in different European countries. Ten of the centres had recruited less than five patients, 11 centres five to 15 patients, 14 centres 16 to 50 patients, two centres 51 to 100 patients, and one centre more than 100 patients. Of the 899 patients 818 (91%) were men, and 81 (9%) were women. The mean age was 69 years (range 37 to 90). The American Society of Anaesthesiology (ASA) risk classification was used to represent the patient's risk profile. The distribution in the different categories is represented in Table 1 . Factors that may have influenced the decision to perform endovascular treatment rather than an open surgical procedure included marked obesity in 192 patients (21%), previous laparotomy in 229 patients (25%), unfit to undergo an open abdominal aortic procedure in 77 (9%), and unfit to tolerate general anaesthesia in 6 (3%).
Detailed preoperative imaging of the abdominal aorta and iliac arteries by contrast-enhanced computed tomography (CT), and aortography was performed in 99% and 97% respectively. The median maximum transverse diameter
S64
Ph. Cuypers et al.
(MTD) of the aneurysms treated was 55 mm with an interquartile range (IQR) of 48 to 60. The median infrarenal neck diameter was 22 mm (IQR 21 to 24), and the median neck length was of 25 mm (IQR 20 to 32). An anatomical classification had been described previously. 7 In the study 17% of the patients demonstrated a type A morphology (normalsized aortic cuff at the bifurcation), 55% had a type B (normal common iliac arteries), 17% type C (partial aneurysmal common iliac arteries), 7% type D (proximal aneurysmal common iliac artery with small distal normal segment) and 5% had a type E (completely aneurysmal common iliac arteries). 97% of patients had symmetrical morphology, and the others had iliac arteries of different anatomical categories at the two sides.
Commercially manufactured devices for stent-graft treatment was used in the majority of patients in this series, but two patients had a device implanted that had been constructed by the physician. 8, 9 Most participating centres were assisted during their first series of cases by a vascular surgeon or a radiologist who had pioneered this therapeutic approach, and had extensive experience acquired with the type of device used. Most commonly procedures were performed in the operating room using mobile fluoroscopy equipment. Completion angiograms were performed to assess the procedural results. Vascular surgeons and radiologists usually worked together in teams. There were differences between centres with regard to the use of systemic or regional heparinisation, the application of coil embolisation of side-branches prior to stent-graft, and the preference for a unilateral or bilateral common femoral artery exploration with arteriotomy for the implantation of bifurcated devices.
Data collection and assessment
Standardised Case Record Forms were made available by the EUROSTAR organisation to participating institutions from July 1996. During the prospective study period the informed consent registration page was faxed preoperatively to the Data Registry Centre. Completed forms with baseline and clinical data, summarised information on the CT and angiographic findings, details of the stent-graft procedure, and observations from the completion angiography were sent to the Data Registry Center after discharge of the patient. Subsequently, follow-up forms with clinical and imaging data were submitted after each outpatient visit. Follow-up data consisted of information on the patient's general condition as well as the presence or absence of endoleaks and changes in the MTD of the aneurysmal sac. In the case of death or conversion to an open procedure details of these events were recorded as they occurred.
The imaging follow-up protocol included a CT-scan at 1, 3, 6, 12, 18 and 24 months, and yearly thereafter. An intraarterial DSA was scheduled at 1 month and 12 months. A duplex study was performed at the same times as CT-scanning until the 12-month follow-up visit. For this study combined use was made of findings at CT, DSA and duplex assessments. If abnormalities were observed with one modality this was the recorded finding. The prime imaging parameters determined preoperatively and with each follow-up visit were: (1) the maximum transverse diameter (MTD), and (2) the presence or absence of perigraft flow in the aneurysmal sac, i.e. endoleakage. Endoleaks were distinguished as early endoleak, that is an endoleak observed before discharge, and endoleaks at follow-up, that is all endoleaks observed at 1 month imaging studies and/or on subsequent follow-up studies. Endoleaks at follow-up included residual early endoleaks that continued to exist after 1 month, and those which arose de novo. Endoleaks were also classified by site: proximal attachment, midgraft level, distal attachment site, and those originating from side-branches.
Data analysis and study endpoints
All data were recorded on a computerised database. Operative technical details, such as the type of anaesthesia, and the need for adjuvant procedures were recorded. In addition, information on the duration of the procedure, duration of fluoroscopy, duration of intensive care unit (ICU) stay, and duration of hospital administration were entered. Early results were represented by the mortality at one month, and the occurrence of systemic and local (arterial) complications. All continuous variables were expressed as median values and interquartile ranges.
Results after discharge were recorded in terms of late complications, and the development of endoleaks during follow-up. Two patterns of endoleak at follow-up were distinguished in this analysis according to the frequency and the time period of identification: (1) persisting endoleaks, which were observed either on at least two subsequent follow-up visits or with one negative study in between the two positive studies, (2) temporary endoleaks, which were all other endoleaks, e.g. a single-time-observed leak, or more than one negative study between two positive studies, i.e. remote occurrence.
Changes in the MTD of aneurysms between the preoperative measurements and imaging examinations during follow-up were correlated with the occurrence of endoleaks at follow-up. Median values and interquartile ranges were used to represent these values. For this correlation a paired Wilcoxon test was used. Life-table analysis and Kaplan-Meier curves were constructed to represent the freedom-from-endoleak (no endoleak at follow-up), freedom-from-persistent endoleak (no persistent endoleak at follow-up), and patient survival. In addition, the cumulative survival and freedom-from-persistent endoleak data were combined into a persistent endoleakfree survival rate.
Results

Devices and procedures
Of the 899 patients, 797 received a modular bifurcation device, 21 a uni-piece bifurcation device, 63 an aortoaortic straight tube stent-graft, and 18 an aorto-uni-iliac device. In the last group the procedure included a femorofemoral crossover bypass, and stent occluder of one common iliac artery. The devices used were Stentor Ò (331 patients), Vanguard Ò (455 patients), EVT Ò (38 patients), Talent Ò (63 patients), AneuRx Ò (10 patients), and physician-constructed prototype devices (two patients). Seven hundred and twenty-eight (81%) procedures were performed under general anaesthesia, 152 (17%) under spinal anaesthesia, and five (0.6%) under local anaesthesia. In 14 patients the type of anaesthesia was not indicated. The median operation time was 140 min (106e210); the fluoroscopy time was 27 min (18e40); the length of ICU stay was 21 h (18e24); and the duration of postprocedure hospital stay was 7 days (5e10). In 239 patients, 246 adjuvant procedures were performed. One hundred and fifty-five patients had endovascular procedures and 84 patients had open surgical procedures (Table 2) .
Early complications
Intraoperative conversion of the initial intervention into an open surgical procedure was required in 18 patients (2%), and another two were subsequently converted to open operations during the first postoperative month. There were 29 early deaths (3.2%). Of these, 20 occurred during the hospital stay, and nine shortly thereafter. Causes of death included cardiac events in eight, multi-organ failure or sepsis in six, pulmonary failure in two, colonic ischaemia in one, haemorrhage in two, and cerebral complications in three patients. The mortality rate correlated significantly with the ASA category with 10 deaths (12.5%) in patients in ASA IV category, and 19 deaths (2.3%) in patients in categories I to III (p Z 0.001).
Failure to complete the implantation occurred in 26 patients. The reasons included migration, inability to deploy the device, inability to connect an iliac limb to a main device, and graft thrombosis. In 18, conversion to an open procedure was required. In five patients a femorofemoral bypass was performed to bypass an inadvertently caused iliac artery occlusion, and in three the procedure was abandoned. Early non-fatal systemic complications occurred during hospital admission in 117 (13%) patients. The majority of these were cardiac in origin. Device-and procedure-related adverse events other than the need for conversion to an open procedure during or after the operation occurred in 13% and access-site-related complications in another 13% (Table 3 ).
Early endoleak
In 162 patients, 174 endoleaks were identified before discharge. Of these, 39 were at the proximal attachment site, 29 at mid-graft level, 52 at the distal site (together defined as graft-related endoleaks), and 54 consisted of backbleeding from side-branches (non-graft-related). Within 6 months 72 (41%) of the endoleaks had resolved spontaneously. Of the resolved endoleaks, 12 were proximal, 15 mid-graft, 20 distal, and 25 side-branch backbleeding. A secondary endovascular repair was undertaken in 12 patients, and an open procedure in one. Six patients had endoleaks at discharge that were related to failure to complete the stent-graft procedure. Three of these underwent a conversion within 6 months, and three patients were managed conservatively. Fifty-four endoleaks persisted at 6 months, 39 (32%) were graft-related and 15 (28%) were nongraft-related. This difference was not significant. In 29 the course was unknown because of loss of follow-up or because of the timing of follow-up relative to this study.
Of the 39 proximal endoleaks one was dealt with by conversion to open surgery during the admission, three by open repair at a later admission, four by late endovascular repairs, and 12 endoleaks closed spontaneously. Fifteen proximal endoleaks (38%, 15/39), and 39 endoleaks at other sites (29%, 39/135) were still present after 6 months, rates that were not significantly different.
Complications at follow-up
The median follow-up period at the time of data analysis was 6.2 months (range 0 to 48). This is indicative of a high rate of patient recruitment during the most recent part of the study period. The completeness of follow-up information is shown in Table 4 . The overall ratio of observed to expected follow-up visits, corrected for interval deaths was 82%. However, after 1 year there was a marked drop in this ratio to 45% at 18 months.
Adverse systemic events were observed after the first postoperative month in 3 to 4% of patients in every 3 months' follow-up period. These complications included a wide range of conditions, usually not related to the procedure. Cardiovascular disease constituted 21 to 32% of events in each observation interval. Procedure or device-related complications occurred in 5 to 9% (Table 5 ). In six patients (0.7%) the aneurysm ruptured during follow-up. In two of these the existence of an endoleak had been demonstrated prior to rupture and one had a stent-graft infection. Further interventions for procedure and device-related complications were required during the subsequent follow-up in 3 to 4.7% of the patients in each 3-month follow-up interval. Most of the interventions were by a transfemoral approach.
Endoleak at follow-up
Endoleaks at follow-up developed in 1-5% in each 3-month follow-up interval (Table 6 ). Proximal endoleaks were relatively frequent during early follow-up, but were not observed after the sixth postoperative month. In contrast, endoleaks originating from the graft itself and distal endoleaks were noted throughout the follow-up period up to 18 months postoperatively. New endoleaks from lumbar arteries did not develop after 6 months. A total of 64 reinterventions (53 transfemoral, 10 transabdominal and one crossover bypass combined with an endovascular procedure) were performed for endoleaks. Of these reinterventions were successful in resolving the endoleak. The freedom-from-endoleak rate, representing the absence of an endoleak at any time during follow-up, was 74% (S.E. 3%) at 18 months postoperatively. The freedomfrom-persistent endoleak rate, which was based on the occurrence of persistent endoleaks only, was 90% (S.E. 2%) at 18 months of follow-up (Fig. 1) .
Aneurysm shrinkage
The median maximum transverse diameter (MTD) of the aneurysms in the overall group decreased significantly from a median preoperative value of 55 mm (48e60) to 50 mm (42e58) at 6 to 12 months postoperatively (pZ 0.0001). In patients who never had an endoleak, there was a significant difference between the preoperative and 6-to 12-month values, 55 mm (48e60) and 49 mm (42e56) respectively (pZ 0.0001). In contrast, patients with persisting endoleaks had no decrease of the median MTD, preoperatively 57 mm (50e65), and after 6-12 months 60 mm (54e63). Patients with temporary endoleaks demonstrated a significant drop in MTD, from 57 mm (54e63) to 53 mm (48e53) (pZ 0.004).
Survival and persistent endoleak-free survival
Sixty patients died in the two years following the stentgraft procedure. In only two patients was rupture of the aneurysm the cause of death. The cumulative survival rate at 18 months was 88% (S.E. 2%). The persistent endoleakfree survival, based on the combined patient survival and freedom-from-persistent endoleak data was 79% (S.E. 2%) at 18 months (Fig. 2) .
Discussion
This series represents the collective experience of 38 groups in European centres with stent-graft repair of AAA. Centres that were involved from the beginning of the registry had enrolled patients in the retrospective part of the study, and this included their early experience with this technique. For centres that joined the registry after 1st July 1996, it was requested that they did not submit data on patients included in their learning curve experience. Whilst differences in treatment outcome may be influenced by the time period within the study that the operation took place, and experience of the team, this was not the subject of the present study. The main objective was to make a realistic assessment of results obtained from endovascular aneurysm repair in Europe today. The range of devices used represented all available stent-grafts during the study period. The predominance (89%) of modular bifurcated grafts used was a reflection of the important role played by European physicians in the development and early application of this type of device. 10, 11 Data collection in this large multicentre series was a laborious operation. The ratio between observed and expected data was acceptable up to 12 months after operation, but declined to a disappointing 40% at 18 months. Nevertheless, a meaningful analysis is possible.
A rational indication for the treatment of an AAA, either by open or by endovascular surgery, may be based on the premise that the mortality of treatment is less than the risk of rupture within one year. 12 The early mortality of endovascular AAA-repair in recent studies varied from 0-6.6%. [6] [7] [8] [10] [11] [12] [13] [14] The few studies comparing patients treated with stent-grafts, with a contemporary group of controls treated by open surgery, showed no difference in mortality. 15, 16 Our findings included an overall operative mortality in 899 patients of 3.2%, and was significantly related to advanced co-morbidity. For ASA IV patients it was 12.8%. Parodi's series, consisting of patients with contraindications for open surgery, had a mortality of 8%. 17 It is to be expected a Endoleaks noted by observers as a clinically significant complication. Endoleak may be recorded during more than one interval. These figures do not equal numbers of new endoleaks in Table 6 which were based on serial imaging. Until such a study is completed choice of treatment must be based on personal preferences and economic factors. A lower incidence of systemic complications, a shorter duration of hospital stay, and a more rapid recovery favour the endovascular procedure. But these advantages have to be contrasted with the expense of the stent-graft and the necessity for long-term follow-up by imaging techniques because of the risk of late endoleak development. Systemic complications were observed in the postoperative period in 13%, cardiac, pulmonary, and renal dysfunction being most frequently encountered. This incidence is almost identical with the 14 to 17% as reported by Brewster and May, but higher than the 5% observed by Mialhe et al. 10, 15, 16 In comparison, the incidence of cardiac and pulmonary complications was considerably lower in the present study than in a series of open operation reported in the Canadian Aneurysm Study (4% vs. 15%, and 3% vs. 8%, respectively). 18 This is in agreement with the observations of Brewster et al., who found, in a comparative study, a lower incidence of systemic complications in the stent-graft-treated group. 16 Initial exclusion of the aneurysm was achieved in 82% of this series (737/899). An 18% incidence of early endoleaks is in the middle of the reported range which varies from 12-44%. 5, 10, 11, 14, 17, 19 The majority (69%, 120/174) of early endoleaks were graft-related, which includes ineffective seal at the attachment sites and leak from the graft itself. 20 Thirty-one percent (54/174) of early endoleaks were still present after 6 months, without much difference between graft-related and non-graft-related endoleaks. Proximal endoleaks persisted just as frequently (38%, 15/39) as other endoleaks (29%, 39/135) until the sixth postoperative month. This finding corresponded with the observations of Matsumura and Moore, who found no difference in the tendency of spontaneous closure between proximal and other endoleaks. 21 Endoleaks were associated with device migration, graft thrombosis, deployment problems or failure to connect the second iliac limb (inability to complete the procedure) in 4% of patients (6/162). The availability of adjunct device components, such as an extra short aortic cuff to seal the proximal attachment is essential.
Successful AAA exclusion results in a marked decrease in aneurysm size. The presence of endoleaks, on the other hand, may be associated with further expansion of the aneurysm, and possibly rupture. [22] [23] [24] [25] [26] Proposals for the classification of endoleaks have been made by White et al. 19, 20 These authors distinguished primary endoleaks, existing from the initial procedure, and secondary or late endoleaks, which develop de novo during follow-up. We found it difficult to follow precisely this classification, as it was impractical in a life-table analysis to distinguish residual procedural endoleaks from endoleaks that develop after the perioperative period. Therefore endoleaks at follow-up, as defined for the purpose of this study, included all endoleaks observed at 1 month or thereafter. Other aspects of White's originally suggested definitions were applied in detail. We found that endoleaks originating from the graft and distal attachment sites continued to occur after 6 months of follow-up, whereas new proximal attachment-site endoleaks and reinjection from sidebranches were not observed after this period.
Criteria for success have been outlined by the Ad Hoc Committee for Standardised Reporting Practices in Vascular Surgery of the Society for Vascular Surgery/International Society for Cardiovascular Surgery. 27 This committee distinguished between technical success and clinical success for early postoperative results, and continuing success for late results. These definitions each encompass a range of variables including graft thrombosis, migration, infection and dilation at or adjacent to the aneurysm as endpoints. In our view this approach will remain the basis for a methodological analysis of treatment results of endovascular AAA-repair. However, a patient-oriented analysis as presented in the present report seems justified. The expected short-and longterm survival rate is the first and most important information required by the patient. We observed that only persistent endoleaks were associated with instability (increase of diameter) of aneurysms, and consequently a risk of late rupture. This suggests that freedom-from-persistent endoleak is the second most important variable from the patient's point of view. Whilst survival and freedom-from-persistent endoleak should be calculated separately, a combined endpoint "persistent endoleak-free survival" gives a realistic and very valuable single measure of outcome. Additional risks of treatment, including the possibility of endovascular or open re-interventions, are also very relevant, but are less likely to influence the patient's choice of treatment.
In principle, Kaplan-Meier curves can be used to estimate the risk of any event of interest after vascular interventions. 28 However this technique has been utilised rarely to demonstrate outcome of endovascular AAA-repair. May et al. have used Kaplan-Meier curves to calculate rates of survival and graft failure, and the Ad Hoc Committee for Standardised Reporting Practices recommended the use of the life-table method to report rupture-free survival and stability of aneurysm size. 27, 29 Future assessment of these different endpoints, and in addition the presently proposed persistent endoleak-free survival by life-table or KaplanMeier curves may allow, for example, the identification of favourable anatomical configurations, and comparison between different types of devices with regard to the risk of untoward events during follow-up.
In conclusion, the cumulative survival rate at 18 months in this series of patients was 88% and the persistent endoleak-free survival rate was 79%. We believe these figures represent a realistic appraisal of the outcome from endovascular aneurysm repair in Europe at the present time. Comparative studies based upon this type of data analysis are required now to assess the efficacy of endovascular repair relative to other types of treatment, particularly conventional repair.
